May 11, 2023 MedinCell launches a Global Offering for approximately 25 million euros Read press release
May 4, 2023 mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada) Read press release
April 29, 2023 Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Read press release
March 28, 2023 MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group Read press release